

BIENAIME JEAN JACQUES  
Form 4  
May 15, 2012

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
BIENAIME JEAN JACQUES

2. Issuer Name and Ticker or Trading Symbol  
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chief Executive Officer

(Last) (First) (Middle)  
C/O BIOMARIN  
PHARMACEUTICAL INC., 105  
DIGITAL DRIVE  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
05/11/2012

NOVATO, CA 94949  
(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price                                      |
| Common Stock                    | 05/11/2012                           | 05/11/2012   | M                              |   | 10,000  | A  | \$ 6.46                                    |
| Common Stock                    | 05/11/2012                           | 05/11/2012   | M                              |   | 15,000  | A  | \$ 9.86                                    |
| Common Stock                    | 05/11/2012                           | 05/11/2012   | S                              |   | 20,000  | D  | \$ 38.0097<br>(1)                          |
| Common Stock                    | 05/11/2012                           | 05/11/2012   | S                              |   | 5,000   | D  | \$ 38.0793                                 |

Edgar Filing: BIENAIME JEAN JACQUES - Form 4

|              |            |            |   |        |   | (2)        |         |   |
|--------------|------------|------------|---|--------|---|------------|---------|---|
| Common Stock | 05/11/2012 | 05/11/2012 | S | 500    | D | \$ 38.1312 | 168,691 | D |
| Common Stock | 05/14/2012 | 05/14/2012 | M | 15,000 | A | \$ 9.86    | 183,691 | D |
| Common Stock | 05/14/2012 | 05/14/2012 | S | 15,000 | D | \$ 38.1262 | 168,691 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
| Stock Option (right to buy)                | \$ 9.86  | 05/11/2012                           | 05/11/2012   | M                              | 15,000  | 05/11/2006 <sup>(4)</sup> 11/10/2015                     | Common Stock 15,000   |
| Stock Option (right to buy)                | \$ 6.46  | 05/11/2012                           | 05/11/2012   | M                              | 10,000  | 11/11/2005 <sup>(5)</sup> 05/10/2015                     | Common Stock 10,000   |
| Stock Option (right to buy)                | \$ 9.86  | 05/14/2012                           | 05/14/2012   | M                              | 15,000  | 05/11/2006 <sup>(4)</sup> 11/10/2015                     | Common Stock 15,000   |

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

BIENAIME JEAN JACQUES  
C/O BIOMARIN PHARMACEUTICAL INC.  
105 DIGITAL DRIVE  
NOVATO, CA 94949

X

Chief Executive Officer

## Signatures

/s/ Laura Randall Woodhead,  
Attorney-in-Fact

05/15/2012

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The price in Column 4 is a weighted average price. The prices actually received ranged from \$37.07 to \$38.49. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(2) The price in Column 4 is a weighted average price. The prices actually received ranged from \$38.04 to \$38.13. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(3) The price in Column 4 is a weighted average price. The prices actually received ranged from \$37.38 to \$38.63. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(4) Original option grant vested 1/3 each on May 11, 2006, May 11, 2007, and May 11, 2008.

(5) Original option grant vested 1/3 each on May 11, 2006, May 11, 2007, and May 11, 2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.